DVN

DVN (DVN) is a company in Vietnam's Health Care sector, listed on UPCOM. The stock last traded at 17,500 VND, little changed on the session, giving a market capitalization of 4.7 trillion VND.

On valuation, DVN trades at a price-to-earnings ratio of 6.4 and a price-to-book of 1.1. That is a discount to the Health Care sector average P/E of 18.9. Return on equity of 17.7% points to solid profitability relative to the company's equity base, above the sector average of 11.5%. Trailing earnings per share stand at 3,118 VND.

Aveluro tracks 3 news items mentioning DVN, where recent coverage skews negative (33% of articles). The most recent catalyst was an earnings miss event — "National Securities (VCI) Posts Q2/2026 Pre-Tax Loss of VND 97B, Reversing Year-Ago Profit". Aveluro's composite model rates DVN 6.8/10 (Bullish), blending news sentiment, price momentum, and fundamentals.

Comparable names in the Health Care sector include AGP, AMP and AMV.

Recent developments around DVN include 3 notable classified events. On Jul 20, 2026, an earnings miss was reported: National Securities (VCI) swung to a pre-tax loss of VND 97B in Q2/2026 from a profit of VND 42B a year earlier, driven by a 50% revenue decline and a 75% increase in operating costs. On Jul 19, 2026, a market event was reported: Vidipha (VDP) will issue 9.94 million shares to existing shareholders at 10,000 VND/share, raising over 99.3 billion VND to invest in a Cephalosporin injection production line targeting EU-GMP standards. On Apr 24, 2026, an earnings beat was reported: Vinapharm (DVN) posted record pre-tax profit of 825 billion VND in 2025, up 62% YoY and exceeding the plan by 77%.

Recent coverage shows a mixed sentiment balance across events.